Peps
What is Elamipretide?
Elamipretide targets mitochondrial biology. Its approved product, Forzinity, has a specific Barth syndrome indication rather than a general anti-aging use.
Biological role or research focus
Mitochondrial-targeted peptide.
Forzinity has a specific Barth syndrome indication; this is not approval for general longevity use.
Names you may encounter
SS-31 · SS31 · Forzinity
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Mitochondrial-targeted tetrapeptide
- Main research area
- Barth syndrome
- Evidence featured
- Human crossover trial + open extension
- Source check
- October 4, 2026
Molecular structure
Mechanism & research rationale
It interacts with cardiolipin in the inner mitochondrial membrane. Barth syndrome disrupts cardiolipin biology, providing the disease-specific rationale for studying this pathway.
Clinical uses & product context
FDA granted accelerated approval in September 2025 for Barth syndrome in patients weighing at least 30 kg. Improved knee-extensor strength supported that decision; a confirmatory trial is required to establish the predicted clinical benefit.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human crossover trial + open extension · 2021
TAZPOWER
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
- Population / model
- 12 participants with Barth syndrome in the blinded phase.
- Study design
- 12-week crossover periods with washout, then an open-label extension.
- Main finding
- Neither primary endpoint—six-minute walking distance or symptom score—was met in the blinded phase. Improvements appeared in the extension, with eight participants reaching 36 weeks.
- Limits & context
- An uncontrolled extension is less reliable for attributing benefit. Read the later FDA decision separately: accelerated approval used knee-muscle strength and requires confirmation of clinical benefit.
Animal study · 2019
SS-31 · inflammatory memory model
What does the mouse cognition experiment establish?
- Population / model
- Mice with lipopolysaccharide-induced inflammation and memory impairment.
- Study design
- Behavioral testing plus hippocampal mitochondrial, inflammatory, cell-death, and synaptic measurements.
- Main finding
- Elamipretide improved the tested learning and memory outcomes alongside mitochondrial and synaptic measures.
- How to read it
- Improvement after experimentally induced inflammation is distinct from preventing dementia or improving normal human memory.
- Limits & context
- The abstract does not provide group sizes or numerical treatment effects. Animal findings cannot establish perioperative cognitive benefit or safety in humans.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 3 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. ↗
Sports medicine (Auckland, N.Z.) · 2026 Aug · Journal Article, Review
Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. ↗
International journal of molecular sciences · 2025 Jan 23 · Journal Article, Review
Read available full text ↗
Potential Therapeutic Candidates for Age-Related Macular Degeneration (AMD). ↗
Cells · 2021 Sep 19 · Journal Article, Review
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety evidence & remaining uncertainty
Injection-site reactions were common in the development program, and serious reactions have been reported. Approval in a rare mitochondrial disorder does not establish a favorable benefit-risk balance for healthy people.
Source: FDA · First treatment for Barth syndrome ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
Separating perceived peptide effects from changed habits
The speakers name several peptides while discussing how changes in nutrition, sleep, and training can accompany perceived benefits. This is a discussion of experience and confounding factors, not a controlled comparison.
Did a study isolate the peptide’s effect from simultaneous changes in behavior?
Caption excerpt reviewed · Claims not independently verified · 2026-10-04
Original episode: BURN FAT FASTER WITH MOTS C | Josh Holyfield | Real Bodybuilding Podcast
Watch the source discussions
28 matching video records · 13 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Fouad Abiad Media
BURN FAT FASTER WITH MOTS C | Josh Holyfield | Real Bodybuilding Podcast ↗
Captions indexed · Automatic matches need review
Fouad Abiad Media
PEPTIDES FOR ANXIETY? |SEMAX & SELANK | Real Bodybuilding Podcast ↗
Captions indexed · Automatic matches need review
Mind Pump Show
Hormones, Peptides & Body Transformation with Phil Vella CEO of Vita Bella Health | Mind Pump 2882 ↗
Captions indexed · Automatic matches need review
Mind Pump Show
Peptides vs Bioregulators: The Future of Health Optimization w/ Nick Andrews | Mind Pump 2672 ↗
Captions indexed · Automatic matches need review
Mind Pump Show
SS-31 Peptide Benefits: Why Ben Pakulski Says This Is the Most Exciting Peptide | Mind Pump 2912 ↗
Captions indexed · Automatic matches need review
Peptide Of The Week
Peptide of the Week: Gut Health Deep Dive With Liz Roman, The Poop Queen ↗
Captions indexed · Automatic matches need review
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
SS-31 (10 mg / 30 mg / 50 mg)
American Peptides · Vendor-labeled research use only
$70.00–$215.00
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
SS-31 (10 mg)
PSPeptides · Vendor-labeled research use only
$64.99
Listed in stock · Snapshot 2026-10-05
Options may vary. Shipping and tax excluded.
Affiliate link · PepsRadar may earn a commission from purchases through this link. Affiliate disclosure.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is the discussion about Forzinity or a different product?
- Does the claim match the specific population studied?
- Forzinity has a specific Barth syndrome indication; this is not approval for general longevity use.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Does accelerated approval mean every benefit is confirmed?
No. It can rely on a measure reasonably likely to predict benefit, with further confirmation required.
Why show a trial that missed its primary endpoints?
It is part of the evidence history. The blinded phase and uncontrolled extension need separate interpretation.
References & editorial record
- FDA · First treatment for Barth syndrome ↗
- A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗
- Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.